Pricing Log in Create free account
Saturday 17 October 2026 Export GYRE’s income statement to Excel — free account

Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.95
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — 5 4 — — — —
Insider Ownership 76.50%

Capital & Financial Ratios $m

Market Cap 678.62
Revenue 116.42
Net Income (25.67)
Free Cash Flow (7.12)
Net Debt (74.80)
Current Ratio 4.26 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (21.70) (negative: loss-making)
P/S ratio 5.26
P/B ratio 4.29
Past 5Y EPS Growth —
This Y EPS Growth (2,100.00%) (below 0%: weak)
Next Y EPS Growth 41.25% (at or above 15%: strong)
Next Y revenue growth (6.08%) (below 0%: weak)
Next 5Y EPS Growth 21.64% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.7×, against a ten-year median of 2.0×; over the ten years it ranged from −44.5× in 2018 to 156× in 2018.
P/S against its own 10 years 20.16%
10-year low 10-year high
P/B against its own 10 years 73.42%
10-year low 10-year high
EV/Sales against its own 10 years 33.06%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 0.00
3.60
2022 0.00
21.45
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 34 27 52 75
Receivables 16 25 31 28
Inventory 4 6 10 11
Other 1 1 1 —
57 65 102 122
2023 2024 2025 Q'26
Payables 0 0 0 1
ST’ Debt — — — —
Other 0 5 0 —
20 20 18 29

Compound Annual Growth %

10y 5y 3y
Sales 51.64% 40.96% 4.46%
Cash Flow 0.00% 0.00% (54.44%)
Earnings 0.00% 0.00% 29.74%
Book Value 16.30% 13.34% 25.36%

Revenue $m

Mar Jun Sep Dec Year
’26 23 29 — — —
’25 22 30 31 34 117
’24 27 25 25 28 106
’23 25 29 32 27 113
’22 1 — — 101 102
’21 1 1 2 2 7
’20 16 2 1 2 21
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (17) — — —
’25 0 (7) 14 (6) 1
’24 3 (5) 2 (3) (4)
’23 10 5 8 3 26
’22 (12) (12) (7) 42 11
’21 (24) (20) (22) (18) (84)
’20 (5) (15) (13) (22) (55)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 (18) — — —
’25 (1) (8) 14 (6) (1)
’24 3 (7) 1 (3) (6)
’23 9 2 6 1 18
’22 (12) (12) (7) 37 6
’21 (24) (20) (22) (18) (85)
’20 (5) (15) (13) (22) (55)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.10) (0.12) — — —
’25 0.00 0.00 0.03 (0.02) 0.02
’24 0.03 0.01 0.01 0.00 0.05
’23 0.15 (1.05) (0.60) (1.49) (1.41)
’22 (6.90) 24.59 (2.40) (19.19) (3.90)
’21 (11.84) (9.60) (11.99) (9.60) (43.03)
’20 (4.20) (14.39) (10.94) (12.89) (43.93)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 119.25 46.65 93.00 67.80 51.45 13.50 5.25 2.85 8.26 6.11

Analyst estimates 2026–2028

Powerpack
High 765.00 283.20 555.00 162.60 134.10 113.25 31.35 30.40 27.45 13.75
People
People Employees 10 13 21 34 56 45 7 593 579 625
Revenue/emp, $m 0.04 0.08 0.00 0.00 0.37 0.16 14.61 0.19 0.18 0.19
Income, $m
Income, $m Revenue 0 1 0 — 21 7 102 113 106 117
Gross margin, % 100.00 100.00 100.00 0.00 56.26 (0.57) 95.31 95.91 96.33 95.35
EBT (17) (22) (30) (55) (56) (88) 9 (77) 23 14
EBT margin, % (4,246.87) (2,117.98) (500,916.67) 0.00 (268.48) (1,198.32) 9.20 (67.84) 21.95 12.38
Net income (17) (22) (30) (55) (56) (88) 4 (85) 18 10
Depreciation 0 0 0 0 0 0 1 1 2 3
Per share, $
Per share, $ Revenue 7.67 4.46 0.01 0.00 16.38 3.59 1.61 1.72 1.24 1.30
Earnings (326.09) (111.69) (40.18) (68.97) (43.93) (43.03) (3.90) (1.41) 0.14 0.06
Cash flow (355.23) (87.30) (38.17) (54.47) (43.03) (40.98) 0.17 0.39 (0.04) 0.01
Capex 40.31 (0.10) (0.50) (0.08) (0.21) (0.41) (0.08) (0.12) (0.03) (0.02)
Free cash flow (314.92) (87.40) (38.68) (54.55) (43.24) (41.39) 0.09 0.27 (0.07) (0.01)
Book value 309.06 134.74 160.35 85.35 59.47 20.10 1.14 1.19 1.16 1.59
Shares, m 0 0 1 1 1 2 64 66 85 89
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 86.43 141.20
P/S 19.35 48.36 117.56 — 5.78 3.80 5.26 13.80 9.74 5.41
P/B 0.48 1.60 0.74 — 1.59 0.68 7.79 112.28 10.46 10.59
EV/Sales (23.22) 16.39 (35.09) — 2.24 (1.87) 5.07 13.56 9.53 4.66
EV/FCF 0.57 (0.84) 0.91 — (0.85) 0.16 95.36 85.58 (158.25) (615.37)
Cash, $m
Cash, $m Operating cash flow (18) (20) (29) (44) (55) (84) 11 26 (4) 1
Capex 2 0 0 0 0 (1) (5) (8) (3) (2)
Free cash flow (16) (20) (29) (44) (55) (85) 6 18 (6) (1)
Balance, $m
Balance, $m Working capital 16 30 119 67 72 37 37 37 45 84
Total debt 19 5 — 0 1 2 0 — — —
Net debt (17) (33) (120) (77) (79) (47) (25) (34) (27) (52)
Shareholders’ equity 16 31 120 68 76 41 72 78 98 142
Returns, %
Returns, % ROA (31.49) (65.75) (36.56) (49.38) (58.16) (116.85) 3.28 (92.34) 9.99 3.45
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 12.23 (93.45) 14.08 7.99
ROE (71.35) (108.92) (39.88) (58.61) (77.89) (150.11) 4.06 (215.71) 21.51 4.18
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Gyre Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OABI OmniAb, Inc. $687.7M — (loss-making) — (loss-making) +244.24% (above 0%: growing) n/m +211.16% (above 0%: growing) 95.45% (49.47%) Compare
ANNX Annexon, Inc. $682.5M — (loss-making) — — n/m −26.41% (below 0%: shrinking) 0.00% 0.00% Compare
MDXG MiMedx Group, Inc $682.2M 111× — (loss-making) −34.73% (below 0%: shrinking) n/m −174.83% (below 0%: shrinking) 68.96% (28.69%) Compare
CADL Candel Therapeutics, Inc. $681.8M — (loss-making) — (loss-making) 0.00% n/m −93.35% (below 0%: shrinking) 0.00% 0.00% Compare
PHAR Pharming Group N.V. Sponsored ADR $681.6M 62.4× — (loss-making) −3.22% (below 0%: shrinking) −57.14% (below 0%: shrinking) −183.87% (below 0%: shrinking) 83.92% 1.44% Compare
GYRE Gyre Therapeutics, Inc. $678.6M — (loss-making) — (loss-making) −2.12% (below 0%: shrinking) n/m −130.45% (below 0%: shrinking) 92.41% (49.35%)
AURA Aura Biosciences, Inc. $657.5M — (loss-making) — — n/m −56.26% (below 0%: shrinking) 0.00% 0.00% Compare
DSGN Design Therapeutics, Inc. $655.9M — (loss-making) — (loss-making) — n/m −7.00% (below 0%: shrinking) 0.00% 0.00% Compare
PRME Prime Medicine, Inc. $654.8M — (loss-making) — (loss-making) +3.50% (above 0%: growing) n/m +4.40% (above 0%: growing) 100.00% (3,750.87%) Compare
Median of peers $681.7M — — 0.00% — −41.33% 34.48% 0.00%

All 614 Biotechnology stocks →

Gyre Therapeutics, Inc. (GYRE) key facts

  • Gyre Therapeutics, Inc. (GYRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, GYRE traded at $6.08, a market capitalization of $678.6 million.
  • Return on equity was 4.18% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 16.83 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Gyre Therapeutics, Inc. (GYRE) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GYRE · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com